Antibody therapy: Substitution-immunomodulation -monoclonal immunotherapy
نویسندگان
چکیده
منابع مشابه
Monoclonal Antibody Therapy of Lymphoma
Köhler and Milstein, their use as a targeted therapy for cancer has been explored widely. Depending on antigen specificity, antibodies have the potential to react preferentially with tumor cells while binding to a lesser degree with normal tissues. This is in great contrast to chemotherapy (and to some degree radiotherapy), where significant toxicity results from drug exposure to various organs...
متن کاملChemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Proposing that a blend of the chemical diversity of small synthetic molecules with the immunological characteristics of the antibody molecule will lead to therapeutic agents with superior properties, we here present a device that equips small synthetic molecules with both effector function and long serum half-life of a generic antibody molecule. As a prototype, we developed a targeting device t...
متن کاملBiological impediments to monoclonal antibody-based cancer immunotherapy.
The ability of antibodies to exploit antigenic differences between normal and malignant tissues and to exact a variety of antitumor responses offers significant advantages to conventional forms of therapy. Several monoclonal antibodies (mAb) have already proved to be relatively well tolerated and effective for the treatment of many different malignant diseases. However, mAbs must overcome subst...
متن کاملMonoclonal antibody therapy for Junin virus infection.
Countermeasures against potential biothreat agents remain important to US Homeland Security, and many of these pharmaceuticals could have dual use in the improvement of global public health. Junin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as a category A high-priority agent. There are no Food and Drug Administration (FDA) approved drugs availab...
متن کاملMonoclonal antibody therapy for classical Hodgkin lymphoma
8531 (2009). Monoclonal antibody therapy for classical Hodgkin lymphoma Review: Clinical Trial Outcomes future science groupClin. Invest. (2013) 3(9)90932 Thertulien R, Frankel AE, Evens AM et al. APhase I, open-label, dose-escalation,multidose study of MDX-1401 (defucosylatedhuman antiCD30 monoclonal antibody) inpatients with CD30-positive refractory/relapsed Ho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Medical Research
سال: 2019
ISSN: 0971-5916
DOI: 10.4103/ijmr.ijmr_2198_18